Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma

• Main Authors: Michael P. Chu (Author), Yuetong Li (Author), Sunita Ghosh (Author), Shelley Sass (Author), Michael Smylie (Author), John Walker (Author), Michael B. Sawyer (Author)
• Format: Book
• Published: Wiley, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Body composition is minimally investigated in an immunotherapy era. Specific body composition signals such as myosteatosis may reflect aspects of patients' immunology and thereby their ability to respond to immunotherapies. Ipilimumab is a key checkpoint inhibitor in metasta...